@article{10.4103/IJPC.IJPC_83_18, title = {A Comparative Study of Transdermal Buprenorphine and Oral Morphine in the Treatment of Chronic Pain of Malignant Origin}, author = {Choudhury, Kakali and Dasgupta, Partha and Paul, Nishana and Choudhury, Krishnangshu Bhajna and Roy, Bodhisatta and Maity, Shampa}, abstract = { Background and Objective: The study was designed to compare the efficacy and adverse effects of buprenorphine transdermal (TD) against oral morphine in pain management of cancer patient. Methods: A randomized open-labeled prospective study was done in palliative cancer pain clinic in a tertiary care medical college between August 2017 and January 2018, to compare the efficacy (pain assessed by VAS) and adverse events (CTCAEv4) between arm A, buprenorphine TD, (20 μg/h, extended 7 days formulation) and arm B, oral morphine (10mg immediate releasing formulation). Patients with solid tumour malignancies with VAS score >40 (moderate to severe pain) were included in study. Results: 63 patients were analyzed. Commonest primary cancers were breast in females and head and neck in male individuals in both arms. Initial VAS score of arm A and arm B were 81.25 and 82.26 respectively. By 1st week, 11 arm A patients were relieved from pain. Another 17 patients of arm A became pain free by 2nd week, total dose of 40 μg/h. Only 4 patients needed 60 μg/h for pain relief. In arm B, 2 patients were relieved by 1 week with total 30mg/day morphine, 11patients were relieved with 60 mg/day by 2nd week and 12 patients with 90 mg/day. 6 patients were relieved with 120 mg/day dose at the end of 4\textsuperscript{th} week. Nausea and constipation were stastically higher in Arm B compared to that of Arm-A. Conclusions: TD Buprenorphine had similar efficacy with oral morphine, with better toxicity profile and better compliance. }, volume = 24, issn = {0973-1075}, issn = {1998-3735}, url = {https://doi.org/10.4103/IJPC.IJPC_83_18}, doi = {10.4103/IJPC.IJPC_83_18} }